Amneal Pharmaceuticals (AMRX) Revenue (2017 - 2026)

Amneal Pharmaceuticals' Revenue history runs 10 years deep, the most recent figure standing at $722.5 million for Q1 2026.

• In Q1 2026, Revenue rose 3.9% year-over-year to $722.5 million; the TTM figure through Mar 2026 stood at $3.0 billion (up 7.62% YoY), while the FY2025 annual figure was $3.0 billion, up 8.05% from the prior year.
• Revenue was $722.5 million for Q1 2026 at Amneal Pharmaceuticals, down from $814.3 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $814.3 million in Q4 2025 to a low of -$1.6 billion in Q4 2022.
• Historically, Revenue has averaged $497.3 million across 5 years, with a median of $659.2 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Revenue sank 394.8% in 2022, then surged 19125.52% in 2023.
• A 5-year view of Revenue shows it stood at -$1.6 billion in 2022, then surged by 138.98% to $617.0 million in 2023, then advanced by 18.4% to $730.5 million in 2024, then rose by 11.47% to $814.3 million in 2025, then decreased by 11.27% to $722.5 million in 2026.
• The last three Revenue figures came in at $722.5 million (Q1 2026), $814.3 million (Q4 2025), and $784.5 million (Q3 2025), per Business Quant data.